3.1.3 (QnM) Number of research projects/clinical trials funded by government, industries and non-governmental agencies during the last five years

| | ame of the Principal vestigator | Title of the project | Name of the Funding agency | Type (Government/Non- | Department of Principal Investigator | Year of Award | Funds provided (INR in Lakhs) | Duration of the project |
|---------------|------------------------------------|--|--------------------------------------|--------------------------|---|---------------|----------------------------------|-------------------------|
| | i estigator | | ugency | Government) | i i incipui investigator | | | the project |
| | | | 2021-2022 | | | | | |
| | | | | | | | | |
| | | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE | | | | | | |
| | | 2/3,DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE | | | | | | |
| | | ORALLY ADMINISTERED PF 07321332/RITONAVIR | | | | | | |
| | | COMPARED WITH PLACEBO IN NONHOSPITALIZED | | | | | | |
| | | SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 | | | | | | |
| | | WHO ARE AT INCREASED RISK OF PROGRESSING TO | | | | | | |
| 2021-2022 Dr | r. Balachandra G | SEVERE ILLNESS | Leads Clinical Research | Non - Government | General Medicine | | 6.86 | |
| | | | 2020-2021 | - | - | - | | |
| 2020-2021 Dr | r.Balachandra G | A Randomized, Open Label, Dose Ranging, 5-Treatment | Leads Clinical Research | Non - Government | General Medicine | | | |
| | | Groups Clinical Trial Evaluating the Safety and Efficacy | | | | | | |
| | | of 2-Deoxy-D-Glucose as an adjunctive therapy to | | | | | | |
| | | standard of care, in comparison to standard of care | | | | | | |
| | | alone, in the Acute Treatment of moderate to severe | | | | | | |
| | | COVID -19 patients. | | | | | | |
| | | A Randomized, Open Label, 2-Treatment Groups | | | | | | |
| | | Clinical Trial Evaluating the Safety and Efficacy of a | | | | | | |
| | | Combination of Nitazoxanide and Hydroxychloroquine | | | | | | |
| 2022 2024 | | Versus Hydroxychloroquine Alone in the Acute | | | | | | |
| 2020-2021 Dr | r.Balachandra G | Treatment of Moderate COVID-19 Patients. | Leads Clinical Research 2019-2020 | Non - Government | General Medicine | | 1.19 | |
| 2020-2021 Mr | r. Yashas | | ICMR | Government | Anatomy | | 0.2 | |
| | r. Vignesh | | ICMR | Government | Anatomy | | 0.2 | |
| | s. Bhargavi | | ICMR | Government | Pathology | | 0.2 | |
| | | A randomized, placebo-controlled, parallel-group | | | | | | |
| | | clinical study to evaluate the efficacy | | | | | | |
| | | and safety of ITC-SLB on sleep quality in healthy | | | | | | |
| 2019-2020 Dr | r. Veena R.M | subjects having sleep disturbances. | Leads Clinical Research | Non - Government | Pharmacology | | 0.55 | |
| | | A double Blind, Placebo- Controlled, randomized, | | | | | | |
| | | Crossover study to evaluate the Effectiveness, Safety | | | | | | |
| | | and tolerability of Turcuron(Standardized extract from | | | | | | |
| | | Curcuma longa) in reducing alcohol induced hangover | | | | | | |
| 2019-2020 Dr | r. Veena R.M | symptoms in adult Male Social drinkers. | Leads Clinical Research | Non - Government | Pharmacology | | 0.43 | |
| | | A Randomized, Double - blind, Placebo controlled study | | | | | | |
| | | to evaluate clinical safety of Pterostilbene in healthy | | | | | | |
| 2019-2020 Dr | r. Balachandra G | volunteers. | Leads Clinical Research | Non - Government | General Medicine | | 0.29 | |
| 2019-2020 Inc | dustrial Project | Antioxidant Study | Leads Clinical Research | Non - Government | N/A | | 0.19 | |
| Dr | r. Sanjana | An exploratory study to elicit the genetic factors | RGUHS | | Dermatology | 2019-2021 | 15.36 | |
| | | underlying Resistant Dermatophytic infections and to | | | | | | |
| | | assess the clinical efficacy of novel therapeutic | | | | | | - |
| | | strategies in its management. | | | | | | 2 |

| | Mr. Ronald | Correlating sleep deprivation and Oxidative DNA | RGUHS | | Biochemistry | 2019-21 | 3.50 | |
|------|--|--|--|------|--------------|------------------|------|---------|
| | | damage to possible co-morbidities in medical students: | | | | | | |
| | | A Case – control study. | | | | | | 2 |
| | | | 2018-2019 | | | • • | | |
| 2019 | PI - Dr Jayashree S Seeri | Evaluation of operational challenges and treatment outcomes of drug sensitive TB following implementation of Fixed Dose Regimen under the Technical and operational guidelines of RNTCP | State Tuberculosis Office (Government of Karnataka) | Govt | Govt | 2019 – till date | 1.92 | |
| | | | 2017-2018 | | • | | | |
| 2016 | <u>PI</u> - Dr Shruthi M N,CoPI- Dr Veena V | Assessment of cost incurred by patients undergoing treatment for tuberculosis in urban areas - a multi centric longitudinal study | State Tuberculosis Office (Government of Karnataka) | Govt | Govt | 2016 - 2020 | 0.35 | 5 years |
| | | | | | | | | - |